Ventracor Limited

OVERVIEW |  NEWS |  MULTIMEDIA  | RESEARCH

---

Ventracor Limited Company Summary

Ventracor is a global medical device company which produces an implantable blood pump, the VentrAssist left ventricular assist device (LVAD), as a therapy to improve the lives of heart failure patients. Ventracor is dedicated to building partnerships with healthcare professionals to make the VentrAssist the standard-of-care worldwide.

COMPANY DATA

	Headquarters	126 Greville Street
		Chatswood NSW 2067
		Australia
	Telephone	+61 2 9406 3100
	Fax	+61 2 9406 3101
	Principal Sector	Health & Pharm
	Principal Industry	Healthcare
	Homepage	www.ventracor.com.au

---

Key Developments: Ventracor Limited

	Australian Market Report of March 20: Investors Digested Recent Rallies MAR 20, 2009 13:15 - Article Views: 7,341 Yesterday Australian shares closed 1% higher as most sectors surged. The benchmark S&P/ASX200 index rose 33.9 points, at 3480.2 while the All Ordinaries index was up 0.9%, or 30.60 points, at 3416.8. The local mining and energy sectors could be buoyed by the rising gold and oil prices today despite the negative lead from the US.
	Ventracor Limited (ASX:VCR) Views The Article in "The Australian" Newspaper As Incorrect And Misleading FEB 18, 2009 11:50 - Article Views: 3,434 Ventracor Limited (ASX:VCR)(PINK:VTCRY) is responding to an article that appeared in today's "The Australian" newspaper, which in the Company's view makes incorrect and misleading allegations regarding the Company and its product the VentrAssist(R) Left Ventricular Assist Device (LVAD).
	Ventracor Limited (ASX:VCR) Announce 250th Implant of VentrAssist Left Ventricular Assist Device (LVAD) MAY 6, 2008 14:59 - Article Views: 2,960 Ventracor Limited (ASX:VCR)(US:VTCRY) today announced that there have now been more than 250 patient implants of the VentrAssist(R) Left Ventricular Assist Device (LVAD).
	Ventracor Limited (ASX:VCR) Announce Results of US Feasibility Trial of the VentraAssist LVAD APR 14, 2008 12:56 - Article Views: 2,676 Ventracor Limited (ASX:VCR)(US:VTCRY) today released the clinical results of the US Feasibility Trial of the VentrAssist(R) Left Ventricular Assist Device (LVAD). The results were presented on Saturday 12 April at the annual meeting of the International Society of Heart and Lung Transplantation (ISHLT) in Boston by Dr. Andrew Boyle, Assistant Professor of Medicine at the University of Minnesota Medical School, in Minneapolis MN.
	Ventracor Limited (ASX:VCR) CEO Peter Crosby Letter to Shareholders APR 3, 2008 13:55 - Article Views: 3,688 Ventracor Limited (ASX: VCR)(PNK: VTCRY) CEO, Peter Crosby Letter to Shareholders
	Ventracor Limited (ASX:VCR) Announce Election of John Ward to Chairman APR 3, 2008 10:51 - Article Views: 5,295 Ventracor Limited (ASX: VCR)(PNK: VTCRY) announced today changes to the Board of Directors. John Massey has retired as a Director and Chairman of the Board. John Ward has been elected Chairman of the Board of Directors, and William Curran takes on the role of Chairman of the Audit, Risk and Compliance Committee.
	Ventracor (ASX:VCR) Announce US FDA Unconditional Approval of Destination Therapy Trial For LVAD MAR 17, 2008 09:52 - Article Views: 2,435 Ventracor Limited (ASX: VCR)(ADR: VTCRY) announced today that the US Food and Drug Administration (FDA) has granted unconditional approval for the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
	Ventracor Limited (ASX:VCR) Appoints Destination Therapy Trial Principal Investigator For LVAD MAR 13, 2008 11:13 - Article Views: 2,375 Ventracor (ASX: VCR) announced today the appointment of Professor Mariell Jessup as Cardiology Principal Investigator of the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
	Ventracor Limited (ASX:VCR) Announces 200th VentraAssist LVAD (Left Ventricular Assist Device) Implant FEB 11, 2008 14:09 - Article Views: 2,133 Ventracor (ASX: VCR) has implanted the 200th patient with its VentrAssist(tm) Left Ventricular Assist Device (LVAD)
	Ventracor (ASX:VCR) Announces European Approval for New Version VentrAssist LVAD DEC 19, 2007 09:42 - Article Views: 1,200 Ventracor (ASX: VCR) today announced CE Marking approval for the next version of the VentrAssist(tm) left ventricular assist device (LVAD) which allows it to be marketed and sold in Europe.

10,887 COMPANY PROFILE VIEWS

This Page Viewed: (Last 7 Days: 8) (Last 30 Days: 59) (Since Published: 2698)